Myrobalan Therapeutics develops first-in-class and best-in-class oral small molecule therapies targeting neuroinflammation and demyelination in CNS diseases. The company focuses on identifying potent, selective, and brain-penetrant compounds for conditions like multiple sclerosis and Alzheimer's disease. They utilize biomarker-guided precision neurology to deliver innovative treatments to appropriate patient populations.
Funding
$43M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Central nervous system (CNS) disorders like multiple sclerosis and Alzheimer's disease are driven by demyelination and neuroinflammation. Current treatments often lack sufficient efficacy, have unfavorable safety profiles, and do not effectively penetrate the brain.
Solution
Myrobalan Therapeutics is developing oral small molecule therapies designed to address neuroinflammation and promote remyelination in CNS disorders. The company focuses on creating first-in-class and best-in-class treatments with a wide therapeutic margin and high CNS distribution. By leveraging drug discovery expertise, Myrobalan identifies potent, selective, and brain-penetrant compounds that target therapeutically relevant mechanisms. The company is committed to biomarker-guided precision neurology to deliver innovative therapies to appropriate patient populations.
Target Audience
The primary target audience includes patients suffering from CNS diseases such as multiple sclerosis, Alzheimer's disease, ALS, Parkinson's disease, and various demyelinating and degenerative disorders.
Features
- Oral small molecule therapeutics for CNS disorders
- Focus on addressing demyelination and neuroinflammation
- Development of first-in-class and best-in-class therapies
- High CNS distribution to ensure efficacy
- Biomarker-guided precision neurology approach